These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 9141610

  • 1. Pentavalent antimonial-induced torsade de pointes.
    Ortega-Carnicer J, Alcázar R, De la Torre M, Benezet J.
    J Electrocardiol; 1997 Apr; 30(2):143-5. PubMed ID: 9141610
    [Abstract] [Full Text] [Related]

  • 2. [Torsades de pointes during treatment of leishmaniasis with meglumine antimoniate].
    Castelló Viguer MT, Echánove Errazti I, Ridocci Soriano F, Esteban Esteban E, Atienza Fernández F, Cuesta Estellés G.
    Rev Esp Cardiol; 1999 Jul; 52(7):533-5. PubMed ID: 10439681
    [Abstract] [Full Text] [Related]

  • 3. Meglumine antimoniate, amiodarone and torsades de pointes: a case report.
    Segura I, García-Bolao I.
    Resuscitation; 1999 Sep; 42(1):65-8. PubMed ID: 10524732
    [Abstract] [Full Text] [Related]

  • 4. [Torsade de pointes secondary to treatment with pentavalent antimonial drugs].
    Temprano Vázquez S, García Salazar MA, Jiménez Martín MJ, López Martínez J.
    Med Clin (Barc); 1998 May 23; 110(18):717. PubMed ID: 9656226
    [No Abstract] [Full Text] [Related]

  • 5. Acute pancreatitis associated with the administration of meglumine antimonate for the treatment of visceral leishmaniasis.
    de Lalla F, Pellizzer G, Gradoni L, Vespignani M, Franzetti M, Stecca C.
    Clin Infect Dis; 1993 May 23; 16(5):730-1. PubMed ID: 8507769
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Severe arthralgia, not related to dose, associated with pentavalent antimonial therapy for mucosal leishmaniasis.
    Castro C, Sampaio RN, Marsden PD.
    Trans R Soc Trop Med Hyg; 1990 May 23; 84(3):362. PubMed ID: 2260169
    [No Abstract] [Full Text] [Related]

  • 9. Cytogenetic observations after meglumine antimoniate therapy for visceral leishmaniasis.
    Hantson P, Léonard ED, Crutzen-Fayt MC, Léonard A, Vandercam B, Delaere B, Mahieu P.
    Pharmacotherapy; 1996 May 23; 16(5):869-71. PubMed ID: 8888081
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Systemic Meglumine Antimoniate in Cutaneous Leishmaniasis of Children: Clinical and Laboratory Complications.
    Layegh P, Khademi Z, Afzal Aghaee M, Moghiman T.
    J Pediatric Infect Dis Soc; 2015 Dec 23; 4(4):356-8. PubMed ID: 26582874
    [Abstract] [Full Text] [Related]

  • 17. Evolution of serum albumin/globulin ratio after antimonial therapy in canine leishmaniasis.
    Amusategui I, Sainz A, Tesouro MA.
    Ann N Y Acad Sci; 1998 Jun 29; 849():447-9. PubMed ID: 9668510
    [No Abstract] [Full Text] [Related]

  • 18. Treatment of kala azar.
    Ozsoylu S.
    Lancet; 1996 Jun 15; 347(9016):1701. PubMed ID: 8642997
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.